ArticleParticle and fibre toxicology2026
Black phosphorus nanomaterials induce hepatic lipid metabolism disorders by triggering oxidative stress and mitochondrial dysfunction.
Article in Particle and fibre toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundBlack phosphorus is the most stable allotrope of phosphorus and possesses a unique layered structure. Black phosphorus nanosheets and black phosphorus quantum dots are the two main forms of black phosphorus nanomaterials (BPNM). BPNM hold significant application potential across various fields, yet a comprehensive evaluation of their biosafety, particularly the impact on hepatic metabolism, remains insufficient. This study investigates the hepatotoxic effects and mechanisms induced by BPNM, with a focus on lipid metabolic disorders.
resultsFollowing a 28-day daily oral administration of black phosphorus quantum dots or black phosphorus nanosheets at doses of 0.1 and 1 mg/kg, mice exhibited reduced insulin sensitivity, increased inflammatory responses, decreased serum levels of triglycerides and very-low-density lipoprotein (VLDL), and exacerbated hepatic lipid accumulation. RNA-sequencing revealed that oxidative stress is a key contributor to BPNM-induced metabolic disruption, accompanied by severe mitochondrial dysfunction. Similarly, BPNM exposure also elevated intracellular reactive oxygen species (ROS), impaired mitochondrial respiratory function and ATP production, consequently disrupted VLDL assembly and secretion in AML12 hepatocyte line. Moreover, ROS scavenger and ATP supplementation restored mitochondrial function and triglycerides transport in vitro.
conclusionsFindings demonstrate that BPNM promote hepatic lipid accumulation possibly by triggering oxidative stress and impairing mitochondrial function, thereby interfering with lipid transport, and resulting in hepatic lipid accumulation. This study highlights the potential metabolic disruption risks of BPNM and provides critical insights for their biosafety assessment and sustainable application.
Indexed as
Identifiers
42458570What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.